Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

Okyo Pharma (OKYO) announced new analyses of corneal images from the recently completed Phase 2 clinical trial of urcosimod in neuropathic corneal pain, or NCP. Patients treated with 0.05% urcosimod demonstrated not only a positive reduction in neuropathic corneal pain, but also favorable changes in corneal nerve structure which were not observed in the placebo group. Patients treated with 0.05% urcosimod showed median increases in total nerve fiber count and total nerve fiber length. In contrast, the placebo group exhibited median decreases in total nerve fiber count and total nerve fiber length. This exploratory dataset, exhibiting consistent and meaningful directional improvements for 0.05% patients on urcosimod across key anatomical endpoints, highlights urcosimod’s potential to support corneal nerve restoration that warrants further investigations.